Insmed stock has surged over the past three years, yet the broader valuation checks currently point to a mixed picture rather than a clear bargain or clear overvaluation at the recent price of US$132.55. After a very sharp three year gain, investors are weighing that performance against valuation indicators that suggest the shares lean expensive on market multiples.

• Insmed has delivered a very large return of roughly 4.8x over the past three years, which puts extra focus on whether the current price already reflects much of the company’s progress.
• Expectations around the commercial potential of therapies like BRINSUPRI and ARIKAYCE may support today’s valuation, while uncertainty around clinical execution and future regulatory outcomes can still weigh on how much investors are willing to pay for the stock.
• Insmed scores 3 out of 6 on the broader valuation checks, which is a mixed outcome that signals the stock does not stand out as clearly cheap or clearly expensive across all measures, 3 out of 6.

The issue now is whether Insmed’s current market price leaves enough room for investors who are coming to the story after this strong multi year run.

Is Insmed Getting Expensive on Sales?

P/S is often a cleaner yardstick for Insmed because the company is still reporting losses and P/E is not a useful anchor yet. On this basis, Insmed currently trades on a P/S of about 35.1x, which is above the Biotechs industry average of 11.5x and the peer group average of roughly 5.6x.

The fair P/S ratio implied by the broader model is 16.1x, which reflects the company’s profile, size and risk. This is less than half of the level at which the stock trades today. Even with the recent business update and higher revenue guidance around BRINSUPRI and ARIKAYCE, the current P/S indicates that investors are paying a premium valuation relative to both industry norms and this tailored fair multiple.

On the P/S multiple, Insmed stock currently appears overvalued compared with both peers and its modelled fair ratio.

The Insmed Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Insmed pick up where the valuation puzzle leaves you by spelling out which paths for Insmed's future growth, margins and earnings would need to occur for the stock to be worth meaningfully more or less than today’s price. Each narrative links its number to a clear view on how growth, profitability and key risks might evolve next, which you can revisit as new information on Insmed arrives on the Community page.

One of the top community narratives on Insmed: 33% undervalued

"The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, and it is expected to increase revenue once it hits the market and starts generating sales late in Q3…"

Do you think there's more to the story for Insmed? Head over to our Community to see what others are saying!

The Bottom Line

For Insmed, the current message from the numbers is that the stock is priced for a lot to go right rather than offering clear valuation slack. Market multiples, especially the elevated P/S relative to peers and the tailored fair ratio, point to an overvalued profile that already bakes in strong expectations around BRINSUPRI and ARIKAYCE. After such a strong three year move, the crux for investors is whether future execution on these therapies and the broader pipeline can satisfy the optimism embedded in today’s valuation, or whether the market eventually resets the multiple closer to sector norms.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.